Evolving Concepts Related to Achieving Benefit Sharing for Custodians of Traditional Knowledge by Elvin-Lewis, Memory
  Correspondence
http://hdl.handle.net/10125/239
   
Ethnobotany Research & Applications 4:075-096 (2006)
Memory Elvin-Lewis, Washington University, St. Louis, 63130. 
U.S.A.
elvin@biology.wustl.edu
Theory
Abstract 
In the context of evolving intellectual property law, defin-
ing ownership of traditional knowledge can be challenging 
when claims of origin are conflicting and requires accept-
ing parameters of how uniqueness is defined and patent 
law is applied to protect this information. For purposes of 
this paper, the complexities of evolving benefit sharing for 
custodians of traditional knowledge are discussed in re-
lationship to the use of medicinal plants. Parameters of 
ownership can vary not only by the perception of individu-
als that lay claim to the information but also by interna-
tional, regional and national laws that govern how benefits 
should be fairly appropriated. Examples are provided to 
exemplify the wide variation that presently exists in this 
evolving process with illustrations of how this information, 
novel or otherwise, can be utilized to optimize its com-
mercial worth. 
Introduction
Unlike a decade ago, changing laws and policies are glob-
ally affecting the way traditional knowledge is valued and 
protected. The need for this has evolved as custodians of 
these data are becoming aware that this type of informa-
tion may amount to a commodity, which requires appropri-
ate recording, protection and management. In the current 
climate of rapid acculturation and globalization, under-
standing these aspects is paramount, particularly since so 
much valuable information is rapidly disappearing. Within 
this context, suitable types of benefit sharing can only be 
achieved if appropriate mechanisms are in place to pre-
vent exploitation should commercialization evolve. This 
paper is designed to provide current insights into the com-
plex and evolving process of deriving fair compensation 
for current holders of traditional knowledge (TK), using as 
the primary example, cultural nuances related to the time-
honored uses of medicinal plants. 
Fundamental to this on-going process was the estab-
lishment of the United Nations Framework Convention 
on Biodiversity (CBD) at the Earth Summit in Rio de Ja-
neiro in 1992 (Table 1). The CBD evolved out of global 
concerns regarding the reduction of biological diversity 
through human activity and the need to reverse this trend 
for the benefit of present and future generations. Its goals 
are to conserve biological diversity, ensure the sustain-
able use of its components, reaffirm that States have sov-
ereign rights over their own biological resources, and en-
sure the fair and equitable sharing of the benefits from 
the use of genetic resources, particularly as it is linked to 
the traditional knowledge of indigenous people. It further 
requires that access to and transfer of biological resourc-
es and relevant technologies can only occur with “prior 
and informed consent” of member States and those pop-
ulations that apply these in their TK systems. It has the 
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Table 1. Convention on Biological Diversity (CBD), 
1992. Issues related to environmental law and policy 
making.
Conservation of biological diversity
Sustainable use of the components
Fair and equitable sharing of benefits
Access to genetic resources
Transfer of relevant technologies
Consideration of all rights over these resources 
and technologies
Availability of appropriate funding to develop these 
issues
•
•
•
•
•
•
•
All signatories are required to respect, preserve, and 
maintain the knowledge, innovations, and practices of 
the indigenous communities.
overwhelming support of the majority of the world’s na-
tions, with the exception of a few others including the Unit-
ed States (Posey & Dutfield 1996). While signed by Unit-
ed States President Clinton, the CBD has yet to be ratified 
by the United States Congress because it is viewed as 
impairing American intellectual property rights as a con-
straint to the transfer of technology rather than as a pre-
requisite (McManis 2003). Moreover, without methods to 
enforce compliance with its directives, it is considered a 
“toothless declaration of good intentions,” with much of its 
treaty language being persuasive rather than mandatory 
(McManis In Press). Nonetheless, activities of its signature 
nations within the context of the CBD continue to address 
problems of mutual concern and, in spite of its obvious 
shortcomings, its policies are likely to promote goodwill 
and positive influences among countries that prescribe to 
its intent. The signature nations continue to work on the 
implementation of Article 8(j) which obligates members to 
“respect, preserve and maintain knowledge, innovations 
and practices of indigenous and local communities em-
bodying traditional lifestyles relevant to the conservation 
and sustainable use of biological diversity; promote their 
wider application with the approval of the holders of such 
knowledge, innovations and practices; and encourage the 
equitable sharing of benefits arising from the utilization of 
such knowledge, innovations and practices.”
To complement these efforts and to facilitate these ac-
tivities, another specialized international government or-
ganization, the World Intellectual Property Organization 
(WIPO), was evolved from the United International Bu-
reaux for the protection of Intellectual Property. This or-
ganization consists of 183 member states to date and has 
established an Intergovernmental Committee on Intellec-
tual Property and Genetic Resources, Traditional Knowl-
edge and Folklore (McManis 2003).
When the World Trade Organization (WTO) was estab-
lished in 1994, a number of international agreements, in-
cluding those incorporated into the Agreement on Trade 
Related Aspects of Intellectual Property (commonly called 
the TRIPS Agreement) were evolved to define minimal 
international standards for intellectual property manage-
ment and enforcement. With the exception of a few less 
developed nations, full compliance with its mandates, in-
cluding its controversial patent and plant variety provi-
sions, has existed since 2005. In order to enforce compli-
ance, the WTO will work to resolve contentious issues and 
impose multilateral trade sanctions when necessary (Mc-
Manis In Press). To insure that the concepts of the CBD 
are addressed in the context of the TRIPS agreement, the 
Doha Declaration was formulated at the Fourth Ministerial 
Conference in Doha, Qatar in 2001. So that sustainable 
biodiversity is assured during its use to promote health 
and economic development, the TRIPS Council was in-
structed to give “particular attention to the protection of 
traditional knowledge and folklore, and to take into ac-
count the stated objective of TRIPS to contribute to the 
promotion of technological innovation and transfer and 
dissemination of technology, to the mutual advantage of 
producers and users of technological knowledge, and in a 
manner conducive to social and economic welfare” (Mc-
Manis 2003). 
There are a number of challenges to overcome to accom-
modate this development of evolving suitable intellectual 
property laws. For example, defining claims of ownership 
is intricate when claims of origin are conflicting and re-
quires accepting parameters of how new sui generis TK 
protection or “of its own kind” is defined and trade secrets, 
trademark and patent law are applied to protect this infor-
mation. Because each nation and group may view claims 
to tangible and intangible resources differently, there is 
not any standard design for this type of effort. Recogniz-
ing that the need is urgent, wide spread global efforts are 
being made to define workable and satisfactory solutions 
to this complex and ever-evolving task.
What is Traditional Knowledge?
In a broader perspective, an understanding of what tradi-
tional indigenous knowledge means is necessary (Zhang 
2000). We are all recipients of various types of information 
and its acquisition is a continuing and dynamic process. 
Each individual’s knowledge is composite in nature and 
reflects what is acquired from various sources and a life-
time of experiences. Its content is dictated by both cultural 
and temporal parameters, its relevance to our daily lives, 
and its relevant value. Depending on contact with others, 
similarities of data can be found among families, commu-
nities, and beyond. 
As mobility and globalization have increased, absorption 
elsewhere is inevitable, with changes of use often evolv-
ing along the way. Examples can be found in all facets 
of our daily lives whether it is in methods of healing or in 
other applied or cultural aspects relevant to every day cre-
ative endeavors. 
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Generally, the uniqueness of traditional knowledge (TK) 
is defined as being evolved, preserved, and transmitted 
in long-established ways between generations with the 
originators of its derivation becoming obscured over time. 
According to Koopman (2005b), it is also defined as “com-
ing forth from holistic cosmologies and from very particu-
lar methodologies (i.e., hands-on experience, intuitive ap-
proaches and use of diachronic data). TK combines differ-
ent types of propositional knowledge (e.g., science, spiri-
tuality) and the same prescriptive (applications, technol-
ogy) knowledge types. It also broadly combines the prop-
ositional with the prescriptive, and thus entails a holistic 
model.” This information may be associated with a com-
munity, clan, and tribe through a sense of custodianship, 
guardianship or cultural responsibility and its exclusivity 
is often circumscribed to either a particular indigenous or 
non-indigenous local group or groups. However, if cul-
tural groups and floras regionally overlap, some informa-
tion may be widely dispersed (or widely held) within this 
broader context but otherwise not necessarily well known 
elsewhere. As such, it may be considered the collective 
knowledge (CK) of groups from one or more nations. How-
ever, one cannot presume that all uses have arisen from 
the original inhabitants of a particular region. Contact with 
other peoples and their plants can also impact on how 
certain pharmacopeias evolve. Therefore, the uniqueness 
of TK or CK associated with medicinal plants can only be 
defined within the parameters of people, places, nations, 
and floras. It is important to appreciate that what is con-
sidered as traditional knowledge is an ever-evolving pro-
cess. Access to other information, introduction of plants 
not indigenous to a region, natural inventiveness, as well 
as changing disease patterns, can all impose modifica-
tions on use and preference (Elvin-Lewis 2006; Lewis et 
al. 1991, Lewis et al. 2004, Milanowski et al. 2002). Thus, 
the acquisition of these types of data and estimations of 
perceived worth has to be placed into a temporal context 
as well. 
The CBD conveys national sovereignty (not ownership) 
over genetic resources, and obliges states that have rat-
ified this convention to (1) acknowledge the cultural in-
terest of TK holding communities in their knowledge, (2) 
recognize their interest in remaining involved in potential 
industrial uses thereof, and (3) to share commercial ben-
efits arising out of utilization of this knowledge. One of 
the difficulties with the CBD is that it does not convey any 
property-like rights to TK holders, but only recognizes their 
cultural relation and interest therein, as well as a right to 
receive benefits – which is more a tailored extractive right 
than a property right (Koopman personal communication). 
Sovereignty issues related to CK are less clear and would 
depend if this knowledge is nationally circumscribed or 
more regionally known. As will become evident further on 
in this paper, this has not prevented certain countries and 
regional associations to evolve certain laws and polices, 
related to “ownership or sovereignty” of both their genetic 
resources and knowledge associated with their uses. 
Guardianship of specific types of traditional medicinal 
knowledge can vary widely. It may be carefully preserved 
within a family, known to specialized healers or to one 
gender, shared among community members, clans and 
tribes, or generally known in a regional context. In cer-
tain cases, as with many traditional healers in sub Saha-
ra Africa, this information is closely guarded because like 
trade secrets they are perceived as being valuable as-
sets which can assure a practitioner’s livelihood. Also, cul-
tural practices and the “need to know” may often dictate 
if this knowledge is widespread or circumscribed to only 
a few specialized individuals within a community setting 
(e.g., African bonesetters). Elsewhere, knowledge of heal-
ing may be passed along through forms of apprenticeship 
or training to those expressing their willingness to utilize 
and/or practice it. These individuals may provide their ser-
vices for profit or provide them freely to the community. 
Representative of this group are the “curandaros” of the 
neotropics or healers of Oceania. In Amazonian villages 
most adults are generally familiar with the use of most me-
dicinal plants in their pharmacopeia and women are espe-
cially knowledgeable of those herbal remedies needed for 
themselves or their children. In this setting, shamans or 
brujos (witches - not to be confused with curandaros), 
are a specialized group of individuals who utilize psycho-
active plants (often only for themselves) for the purposes 
of diagnosis and treatment. Their value as healers is very 
much intertwined with local cosmic beliefs and their ability 
to remove the “invisible” dart that is considered the basis 
for a wide range of indefinable ailments. They frequently 
combine forms of energy medicine in the form of mantras 
with their “psychic” and “tracing” healing practices that 
are amplified by them taking hallucinogenic potions. Like 
their African counterparts, or fetish priests, they have a re-
spected status in the community with talents akin to psy-
chiatrists. Alternately, medicine men and women of North 
American indigenous tribes practice forms of healing that 
combines the use of medicinal herbs with energy medi-
cine (e.g., repetitive chants or mantras) which may often 
include eliciting the intersession of their ancestors. These 
practices can be closely guarded or widespread within a 
group, tribe, or region.
 
Usually concepts transmitted orally are more likely to 
evolve more quickly but nuances of use or formulary vari-
ations can fluctuate even within a family unit, such as has 
been observed among Amazonian populations using hep-
atitis remedies (Elvin-Lewis et al. 2002), not necessarily 
secret in a community or constituency; this information 
may be unknown elsewhere and therefore has value as 
circumscribed “know-how.” Numerous examples of this 
type of unique knowledge can still be found among isolat-
ed indigenous communities of tropical South America. 
Claims of Ownership
Ownership may be viewed differently under customary 
(indigenous), national and international laws. Claims re-
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lated to a particular interest by local or indigenous groups 
may be further substantiated if the plants themselves are 
unique to a particular region, thus restricting further the 
likelihood of this information being derived from else-
where. However, when a number of groups have access 
to the same flora, uses can be similar and overlap, or be 
quite different depending upon the social interrelation-
ships that have occurred over time and the number of re-
lated plant species or genera that share the same types 
of bioreactivities. The evolution of many pharmacopeias 
is not static in nature and the derivation of the individuals 
involved (e.g., in Peru), people of mixed heritage (mes-
tizo), colonist (+500 years primarily of Spanish origin), or 
indigenous can also dictate how plants are used medi-
cally and have resulted in distinctive pharmacopeias be-
ing preferred in neighboring Amazonian and Andean com-
munities. To resolve issues of “ownership,” similar types 
of knowledge may be considered as CK or alternately re-
quire an agreement between parties making claim to par-
ticular forms of exclusive information as to how its disclo-
sure may be mutually beneficial. This is further compli-
cated when there is lack of agreement as how to manage 
these data or who has the right to divulge it and utilize it 
for profit in the first place. 
This does not mean that the source of traditional knowl-
edge for a medicinal use can always be ascertained. 
Sometimes the basis of this knowledge is obliterated by 
widespread application over an undetermined interval 
of time. This process is enhanced as aculturization and 
assimilation of cultures proceeds and can even extend 
beyond the region or nations where the plant and its al-
lies once originated. Several species or chemotypes can 
be involved that also possess the same or similar active 
components and thus claims of origin would be difficult to 
achieve if these taxa are known to be pervasive. A note-
worthy example is the use of the sap of the Amazonian 
tree Croton lechleri and related taxa for wound healing 
throughout western tropical South America (Milanowski 
et al. 2002). Also, some plants have such a global distri-
bution and are used for the same purpose that claims of 
specific ownership would be impossible to validate, such 
as the use of Maclura tinctoria (L.) Steudel for tooth ex-
traction throughout the tropics of Madagascar, Africa, and 
South America (Kaufmann & Elvin-Lewis 1995), the cos-
mopolitan uses of either Catharanthus roseus (L.) G.Don 
f. in remedies for diabetes (Lewis & Elvin-Lewis 2003), or 
of Phyllanthus species for hepatitis (Elvin-Lewis 2006). To 
deal with these types of contingencies, when regional pa-
rameters can be defined, it has been suggested within the 
context of the Auckland Declaration of 2004 that a mutual 
trust to deal with benefit sharing be evolved with the goal 
of seeking partnerships with area neighbors and beyond 
so as to develop knowledge, improve communications 
and ensure a sustainable economic existence for all. Rep-
resentative nations evolving this declaration include Aus-
tralia, the Cook Islands, Federated states of Micronesia, 
Fiji, Kiribati, New Zealand, Niue, Palau, Papua New Guin-
ea, Republic of the Marshall Islands, Samoa, Solomon Is-
lands, Tonga, Tuvalu and Vanuatu (Anomymous 2004a). 
In the other extreme, it is not easy to determine if certain 
cultivars which are carefully selected and circumscribed 
for a particular application are related to their specific heal-
ing qualities and the nature of their components or simply 
linked to particular cultural beliefs which specify the fas-
tidious use of a specimen to how its donor perceives its 
worth for a specific purpose. Numerous examples of this 
practice exist among Amazonian peoples where cultivars 
are shared for only one medicinal purpose and a seem-
ingly identical specimen used for another purpose. Also 
impacting on the evolution of uses are those plant intro-
ductions which have occurred since the colonial period. 
For example, in Peru, ginger (Zingiber officinale L.) and 
turmeric (Curcuma longa L.), valued in many Asian phar-
macopeias, are incorporated into numerous mestizo and 
indigenous herbal remedies (Elvin-Lewis et al. 2002)
Utilization of Traditional Knowledge 
in the Public Domain
Traditional formulations may consist of one plant contain-
ing one or more compounds with complementary or dif-
ferent activities or may be an admixture of several plants 
(referred to as a polyherbal) that are prepared to optimize 
the efficacy of the treatment. In some pharmacopeias a 
treatment may also consist of plants are given sequen-
tially (Elvin-Lewis 2005, Elvin-Lewis et al. 2002). Most of 
these remedies are moderate in potency and low in toxic-
ity thus making them compatible for human use, particu-
larly if used on a short-term basis. As botanicals they may 
vary widely in composition, potency, and content and thus 
there are limitations to their efficacy or safety (Elvin-Lew-
is 2002, 2005, WHO 2000, 2004b, WIP0 2002a, 2005b). 
Knowledge of their value may be passed along by oral tra-
ditions or be properly recorded. 
Should commercialization extend beyond the regional col-
lection of wild plant populations and their sale as botani-
cals in local market places, some forms of control may 
be necessary to ensure a reliable source (WHO 2002, 
2004a,b). For example, national authorities may become 
involved in ensuring sustainability by monitoring plant re-
moval from the wild, fostering the establishment of planta-
tions, or limiting the export of genetically reproducible ma-
terial for growth elsewhere. Also, to protect rare plants at 
risk of extinction from nefarious exploitation by commer-
cial entities, geopositioning data may be redacted from 
herbarium sheets. Without these policies the existence 
of valuable plants and the livelihood of local communities 
could be endangered. 
For some parts of the world, particularly in Europe and 
Asia, much information is already in the public domain 
through a wide variety of published pharmacopeias and 
ethnobotanical treatises and thus its value as potential-
ly proprietary “know-how” is by and large negated since 
it would be categorized as “prior art.” Usually, practitio-
ners applying these phytotherapies are formally trained 
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in apprenticeships or are required to conform to forms of 
circumscribed instruction specified by herbalist guilds, in-
stitutes of traditional Asian medicines, or colleges of natu-
ropathy and homeopathy, etc. The basis of their curricula 
is usually derived from published traditional pharmacope-
ias, monographs, and available databases with specifics 
of diagnosis, treatment and outcome well delineated. For-
mulatory guidelines may be strictly adhered to or allow for 
the substitution of alternative taxa when availability is a 
factor. In Asian remedies, non-organic components may 
also be added. Usually the “right to practice” these forms 
of medicine are mandated by national and state policies 
and laws. Since current scientific evaluations and well-de-
signed clinical trials are proving the relative worth of many 
of these treatments, it is likely that many remedies will 
become popularized outside of the realm of their origins 
(Elvin-Lewis 2005). 
Many of the plants known to these types of traditional me-
dicinal practices are already being incorporated into pat-
ented formulas, usually representing a number of taxa, 
sometimes with other ingredients or even pharmaceu-
ticals; others may simply represent compounds or their 
derivatives derived from medicinal plants. Patented poly-
herbals may closely follow known traditional formulatory 
guidelines (or nuances thereof) or represent an admix-
ture of plant and other substances derived from disparate 
sources. In the latter instance, these novel formulations of 
NeoWestern and NeoEastern herbalism have rarely been 
authenticated for either safety or efficacy (Elvin-Lewis 
2005).
Usually it is recognized that TK as modified and applied 
in a “technological context” is more likely to be subject 
to patent rights. Generally, to satisfy the novelty criteria 
required for patenting, evidence must be provided that 
combining known knowledge has been done in a unique 
manner. Such a patent does not cover either component 
individually and use of one of these components will not 
infringe on the patent covering its use in combination 
(Hansen & VanFleet 2003). Currently, Asian pharmacope-
ias (e.g., Indian, Chinese) are being transcribed into WHO 
(World Health Organization) and WIPO (World Intellectual 
Property Organization) Asian databases for general use 
(Elvin-Lewis 2005). Since these formulations and prac-
tices are more rigidly adhered to and may be applied in 
much the same manner today as they were centuries ago, 
challenges to the validity of some recently issued Asian or 
American patents (e.g., uses of curcumin from turmeric - 
US patent 5,401,504) are likely to take place. In the case 
of turmeric, the patent submitted by two U.S.-based In-
dians was reversed by the US Patent Technology Office 
when evidence was brought forward by the Indian Council 
for Scientific Research (CSIR) that the claims were obvi-
ous and anticipated, were cited in numerous references 
cited in Sanskrit, Urdu and Hindi, and as such its uses had 
been known as “prior art” for centuries. Patenting the use 
of a plant part (e.g., root, bark, sap) which is well known 
for a particular healing or other purpose would also fall 
under this category and be disallowed. It is noteworthy 
that in spite of attempts to curtail this practice, patent ap-
plications based on well known formulations and uses still 
occur in many Asian countries. How these conflicts of am-
bivalence are likely to be viewed by regional patent exam-
iners considering novelty, or are defensible if patenting is 
conferred, remains to be seen. In contrast, should a par-
ticular healing compound/s or its derivatives be derived 
from the specific plant part, their patenting would gener-
ally be allowed since the identity of these substances was 
“not obvious” in the traditional sense and thus is a patent-
able invention attained through technical manipulations. 
Within this context there has been confusion (McManis 
1998) about “the rights of national ownership” when the 
origins of native taxa are, in fact, unknown because the 
histories of worldwide distribution have been lost in an-
tiquity, and patents have evolved around chemical pro-
cesses of extraction and/or stabilization of bioreactive 
compounds, e.g., azadirachtin from the Indian neem tree 
(Azadiractha indica A. Juss.) (McManis, 1998), or the ser-
endipitous discovery of new uses, e.g., anticancer phar-
maceuticals (vincristine and vinblastine) from the Mada-
gascar, rosy periwinkle (Catharanthus rosea) (Lewis & El-
vin-Lewis 2003). Alternately, many patents derived from 
Western herbalism have in the past been unchallenged 
since these usually represent novel mixtures of medicinal 
plants well known to phytotherapists, or as pharmaceuti-
cal compounds were evolved from indigenous pharmaco-
peias when advocacy for benefit sharing to custodians of 
this TK were lacking. Most have been derived from the 
vast amount of secondary data from centuries old phar-
macopeias of Europe, Greek and Arabic medicines and 
academic treatises published primarily in the 19th and 
20th centuries on African and North American indigenous 
pharmacopeias. 
Noteworthy examples derived from indigenous sources 
of the Americas include the Midwestern Amerindian me-
dicinal herb Echinacea, promoted by American eclectic 
physicians of the 19th century, which has found its way 
into numerous formulations and polyherbal mixtures in 
the ever-expanding world of global herbalism. Similarly, 
19th century Midwestern physicians adopted the Penob-
scot use of Podophyllum spp. (May apple) resin to treat 
venereal warts. Its active but toxic podophyllotoxins were 
semisynthesized to form teniposide and etoposide which 
are today topisomerase inhibitors useful in the treatment 
of lymphoma, leukemia, and brain and bladder cancers. 
Valuable pharmaceuticals have also been derived from 
knowledge of indigenous groups living in Peru and Ecua-
dor. For example, during the early 17th century Spanish 
colonial period, the value of Cinchona bark as a malaria 
remedy quickly spread to Europe and elsewhere. Eventu-
ally the isolation of the bioreactive alkaloids quinine and 
quinidine in the 1830s lead to the development of numer-
ous synthetic quinoline compounds that continue to be 
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the mainstay of malaria therapy and to treat arrhythmias 
today. Observation of the muscle relaxant properties of 
blowgun poisons used by the Jivaro in the 1930s led, in 
the 1950s, to the isolation of tubocurarine from Chondro-
dendron tomentosum Ruíz & Pavón and Curarea toxifera 
(Wedd.) Barneby & Krukoff. This compound, derived from 
native sources, was used as a surgical muscle relaxant 
until replaced by the synthetic molecules atracurium and 
vercuronium later in the 20th century (Lewis & Elvin-Lewis 
2003). Over the years the worth of these discoveries, and 
others, continues to be amplified. As was the custom of 
the day, none of the custodians of these types of valu-
able “know how” were ever compensated for the billions 
of dollars these inventions generated. Only recently has 
the concept of providing benefits to the custodians of tra-
ditional knowledge and the nations, which have provid-
ed the genetic resources, emerged. Today, such activities 
would be considered to be inappropriate, and tantamount 
to what is called “biopiracy” (exploitive practices by com-
mercial entities in developed countries who profit from the 
misappropriation of genetic resources or TK from devel-
oping countries without returning appropriate benefits to 
these nations and those of its peoples that provided the 
TK) (Gollin 1999, 2003, Hansen & VanFleet 2003). Some 
countries have become quite proactive in protecting their 
natural resources and traditional knowledge from these 
activities. For example, the Peruvian law #28216, enacted 
in 2004, charges a commission to create a list of Peru’s 
biological resources (especially in regards to unique taxa) 
and to draft laws to protect the country from “biopiracy.” 
As a part of its mandate, they will review patents granted 
locally and internationally and undertake actions to have 
these revoked should they not comply with current nation-
al laws (Anonymous 2004b).
These examples also indicate that realizing the worth of 
any traditional remedy is not easy to estimate and can 
be a long and expensive process, with added value be-
ing provided by the intellectual contributions of many sci-
entists whose work is supported by private, educational, 
government or commercial sources. Involved in these en-
deavors are ethnobotanists who work with the TK hold-
ers in collecting the utility-linked information of the plants 
involved as well as conducting appropriate dereplica-
tions to understand how this discovery relates to others 
already known; botanists that identify the plant or plants 
in the remedy, their distributions, availability and resource 
renewable impact issues; epidemiologists and physicians 
who evaluate their relative value in the context of use; nat-
ural products chemists that work with biologists to isolate 
the bioreactive components, and by appropriate chemical 
dereplications to affirm their novelty or ubiquity in order 
to expand their potential uses; and organic and medicinal 
chemists that may be involved in characterizing and stan-
dardizing its formulation as well as developing semi-syn-
thetic or synthetic derivatives that may be more function-
ally optimal or economical. The costs of conducting the 
final phases of evaluation for commercial viability are per-
haps the most difficult to estimate at the onset of the initial 
discovery. The multitudes of toxicology tests and clinical 
evaluations (Phase 1-4) required proving safety, param-
eters of use, and efficacy can run into millions of dollars.
 
Therefore, the expenditure of bringing a pharmaceuti-
cal to market can be astronomical. Deriving the appro-
priate formulae for fair benefit sharing to accommodate 
the “unknowable” value that is added along the way is a 
challenging process. This is because there is a tendency 
for pharmaceutical companies to factor in their losses as-
sociated with research and development along with their 
gains. As late as the 1990s the vast majority of compa-
nies were not employing utility-linked knowledge to help 
identify plants and their compounds of worth. Because of 
this broad-screening approach, which evaluated a wide 
range of taxa often with specialized mechanistic screens, 
the “hit rate” was less than 5% and those bioreactive com-
pounds which were identified were frequently incompat-
ible for human use (Elvin-Lewis 2006). In their search for 
a potent, unique phytochemical that was readily synthe-
sized, they deemed as unsuitable for development any 
bioreactive compound that was complex, ubiquitous or 
moderate in activity. Because of this approach, they ra-
tionalized that the low royalty rates they proffered, from 
any compounds of promise, were justified on the basis of 
their investment and the meager returns they were likely 
to get (Vogel 1995, 1996). Unfortunately, those that chose 
to deprecate bioprospecting activities frequently failed to 
appreciate these widespread practices. 
 Vogel (1996) has suggested that “countries that supply 
biological samples should fix a royalty rate and distribute 
economic rents and countries which demand biological 
samples should respect the cartel”. Application of this con-
cept, based upon the suggested royalty rate of 15%, may 
be appropriate to any net (not gross) revenue generated 
from the sale of a unique botanical but would be current-
ly considered unrealistic and excessive if pharmaceutical 
research and development is required to develop a com-
mercial product. While evolution of a reasonable formula 
to insure fair benefit sharing between all parties should 
always be the final goal in assessing a realistic royalty 
rate derived from TK-linked genetic resources, a distinc-
tion must be made between commercial products that re-
quire little, if any development (e.g., botanicals) and those 
where considerable value is added (e.g., phytopharma-
ceuticals) to make derived products saleable items. 
Many companies also steered away from evaluating ex-
tant unknown pharmacopeias because of uncertain poli-
cies related to benefit sharing and the costly, time con-
suming, and frustrating process of evolving agreements 
with indigenous groups and their host nations. While 
some Non Government Organizations (NGOs) involved in 
this process worked diligently to represent the best inter-
ests of their clients, and were respected for their efforts, 
others were not as like-minded. There was always the risk 
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of intermeddling by certain NGOs that could choose to 
disagree with all or parts of the agreements and destabi-
lize the negotiations through their advocacy, lobbying, and 
publicity raising activities. Eventually most companies dis-
banded phytochemical discovery programs as being un-
profitable. This was a frustrating time for ethnobotanists, 
other scientists, and TK holders alike who were hoping 
that the information and specimens they were providing 
would be appropriately assessed to optimize their poten-
tials.
Today, as more and more discoveries are being made 
and the herbal and functional food industry expands, 
there is a growing realization that medicinal plants can 
be the source of valuable phytopharmaceuticals or even 
pharmaceuticals. Often using utility-linked knowledge as 
a guide and appropriately linked bioassays, bioreactive 
plant compounds can be readily identified at significantly 
higher hit rates (>70%) and determined if they are suitable 
candidates for commercial development. In this way, plant 
products standardized for their bioreactive contents may 
be sold as phytopharmaceuticals. These may contain one 
or more compounds deemed too complex for pharmaceu-
tical development but are nonetheless recognized as be-
ing useful as found in their natural state. As technologies 
have advanced, compounds from medicinal plants once 
deemed as too moderate in activity or toxic for human use 
are being modified to amplify their efficacy and safety pro-
files. With a better understanding of these examples and 
the recognition that the literature is replete with instances 
where medicinal plants have provided worthwhile phar-
maceutical leads, new interest is evolving based on utility 
linked knowledge (Elvin-Lewis 2005, 2006, Lewis & Elvin-
Lewis 2003, Lewis et al. 2004).
Protecting Circumscribed 
Traditional Knowledge
The ability to utilize for profit information that is readily 
available and in the public domain is fundamentally dif-
ferent from issues related to circumscribed TK. Unfortu-
nately, many researchers are unaware of how to handle 
this type of potentially proprietary information and are na-
ïve regarding its value towards the creation of “utility pat-
ents” or as a basis of access and use fees which can be 
used to compensate, in part, the time and effort of their 
informant/collaborators (Lewis et al. 1999). Unless man-
dated by national sui generis policies, there is still a ten-
dency by many ethnobotanists and the like, to acquire this 
type of information in informally evolved ways which may 
or may not include identifying the informants, formalizing 
with them documents of “prior informed consent” (PIC), or 
evolving fair and up front compensation to the contributors 
of the TK. These methods may avoid the additional steps 
of providing the participants with the purpose of the proj-
ect and having them signify in some appropriate manner 
their acquiescence to providing the information. According 
to Hansen & VanFleet (2003), while there is not any legal 
obligation to elicit PIC in countries that are not signatures 
to the CBD there is a growing consensus that it is wise to 
do so not only for professional or ethical reasons but also 
to avoid future challenge or criticism. 
Eliciting PIC may involve all community members, their 
representatives, or only certain individuals willing to par-
ticipate in the project. It implies that “in all situations where 
an indigenous people or local community is involved in a 
transaction encompassing intellectual property rights, bi-
ological resources, or TK, there will be full consultation, 
and complete exchange of information, leading to full and 
explicit consent prior to any appropriation of information” 
(Chennels 2003). Depending upon the literacy level of the 
collaborators/participants this affirmation may constitute 
the use of fingerprints, name symbols, or signatures ad-
jacent to their name, and may also include some type of 
acknowledgement (e.g., official stamp) from community 
and clan and/or tribal officials that they sanctify such work. 
Within the context of the ICBG-Peru project these docu-
ments were called “actas” and were elicited in each par-
ticipating community (Lewis 2000, Lewis & Ramani 2003, 
In Press). Under the Bonn Guidelines (Anonymous 2002), 
a community has the option of not participating.
According to statements of the WIPO (World Intellectual 
Property Organization) and WHO (World Health Organi-
zation), PIC should be a necessary requisite whenever 
any proposed patent is derived from the information. In 
fact, several European countries, such as Denmark, Nor-
way, Germany and Romania, have already implemented 
or are currently discussing legislative proposals in respect 
of disclosure requirement pertaining to (among others) 
PIC (Koopman 2006). While the evolution of legally bind-
ing biological collecting and know-how licensing agree-
ments are ideal, particularly when collections of data and 
plants are being made to analyze the worth of an indig-
enous pharmacopeia, these activities are expensive and 
time-consuming to evolve. All parties must be legally rep-
resented for the agreements to be appropriately bind-
ing. In this regard, perceptions regarding how TK holders 
should be represented have radically changed as edu-
cational levels have risen and communities are becom-
ing aware that they are deserving of benefits. Forms of 
trusteeships are becoming outmoded as more and more 
indigenous groups are acquiring national recognition as 
juridical bodies. This status allows them to negotiate, with 
appropriate legal representation, on their own behalves. 
Within the context of these accords, forms of oversight 
need to be instituted to assure that issues related to the 
protection of potentially proprietary information and com-
pensatory arrangements are being appropriately man-
aged. Within the perspective of the ICBG-Peru project, for 
example, these efforts assured that the informants/collab-
orators not only received forms of up-front compensation 
for their involvement with the project, but also were also 
aware what long-term benefits may evolve (Lewis 2000, 
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Lewis & Ramani 2003, In Press). With the recognition that 
there is a need for intellectual property-related legal assis-
tance in developing countries, and their public interest cli-
ents (Gollin 2003), several educational institutions, such 
as the recent Intellectual Property and Business Forma-
tion Legal Clinic created at Washington University School 
of Law, and others, are beginning to provide pro-bono pu-
blico (for the public good) services to their communities 
and elsewhere.
 
In spite of all attempts to conduct these types of nego-
tiations appropriately and efforts to comply with national, 
regional pacts, and international treaties, there will al-
ways be misinformed groups and “watch dog” organiza-
tions that will try to sabotage these efforts. The rationale 
for doing this is as varied as the personnel that make up 
these groups, the types of information that they have ac-
cumulated, and how they use it. Much dissent is based on 
the lack of knowledge of the contents of the agreements 
or their disagreement with how they were evolved. Within 
this context, few that wish to derail the process under-
stand laws which have been evolved to protect proprietary 
knowledge (e.g., patent law) or how these laws can be 
used to benefit all those that contribute to the evolution of 
a viable commercial product. Others may simply disagree 
with the concept that patenting is appropriate and would 
prefer to see TK available for the “common good.” 
Unfortunately, many researchers are still likely to dissemi-
nate potentially proprietary TK in publications (grants, pa-
pers, dissertations, brochures, herbarium annotations, 
web-sites, the Internet, etc.) and verbal presentations and 
by doing so cause it to be considered CK and negate it’s 
worth as proprietary know-how. Also, these types of dis-
closures are likely to render the information as unpatent-
able since in US patent law it would be considered “pri-
or art,” particularly if the invention or discovery appears 
in a printed publication in either the US or foreign coun-
try more than one year before a patent’s filing date or is 
dated before the act of invention or conception (Hansen 
& VanFleet 2003). Also, according to US patent law, the 
appropriation of much foreign information, including in-
formation orally transmitted (and uncodified TK), can oc-
cur since only foreign written information is assessed for 
novelty during patent review of an invention. The relevant 
sections of the US patent statute S102 regarding condi-
tions for patentability, novelty and loss of right to patent 
are as follows: “the invention was known or used by oth-
ers in this country, or patented or described in a printed 
publication in this or a foreign country, before the invention 
thereof by the applicant for patent” or “the invention was 
patented or described in a printed publication in this or a 
foreign country or in public use or on sale in this country, 
more than one year prior to the date of the application 
for patent in the United States” (www.bitlaw.com/source/
35usc/102.html). European patent law is not so exclusive 
and considers that everything which does not belong to 
the state of the art is novel. The state of the art is broadly 
defined as anything which has been made available to 
the public in whatever form (oral, written, by use, and so 
forth), at any time, in any country around the world. In 
principle this absolute novelty standard should prevent 
the appropriation of TK in the public domain through pat-
ent law. Closely related inventions would lack novelty un-
der European standards. This law implies that any type 
of traditional knowledge that is orally transmitted or pub-
licly known through demonstrated and public use would 
fall into this category. Information regarding European 
patent law can be obtained through www.european-pat-
ent-office.org (Koopman 2006). The patents in respect of 
compounds derived from azadirachtin are illustrative: the 
European Patent Office has revoked European Patent EP 
436257B1 on a “novel insecticide and…fungicide derived 
from a neem seed…” for lack of novelty in light of prior use 
and communications hereon in India. The revocation was 
upheld on March 8, 2005, and the appeal against it dis-
missed (Koopman 2005b). In time this approach may also 
apply to how TK is viewed in the US patenting process. 
Currently this fundamental difference impacts on how tra-
ditional knowledge is likely to be applied and is possibly 
the root of much dissention when these differences are 
not understood. 
Whether advertent or otherwise, these types of disclo-
sures nullify the capacity for the creators and holders of 
traditional knowledge to pursue intellectual property pro-
tections. For exposure to have a negative impact on a pat-
ent application, patent examiners must easily locate and 
rely on the accuracy of any prior art information (e.g., an 
appropriately designed electronic TK database). In cer-
tain cases such a defensive disclosure may remain anon-
ymous so as not to attract unwelcome attention to an indi-
vidual or community. When the prior art has been missed 
in the examination process, challenges to overthrow an 
existing patent are not readily achieved and are often too 
costly to be worthwhile (Hansen & VanFleet 2003). Nev-
ertheless, the aforementioned example of the opposition 
against and revocation of the “European Neem Patent” 
shows that this need not be the case. 
Appropriate oversight and management of these types of 
data are never easy, particularly among academics where 
the requirement to “publish or perish” is the driving force 
for professional survival and the need to protect these 
types of data is poorly understood. Unfortunately, many 
professional organizations and journals that give lip ser-
vice to protecting TK still do little to prevent this unwarrant-
ed dissemination at meetings and through their publica-
tions. Under these circumstances it would be beneficial if 
guidelines were available so that presenters and authors 
would know from the onset what is ethically acceptable 
and when public disclosure is not. Should indemnifica-
tion be required by the journal or professional sponsor to 
assure that appropriate guidelines are being followed, it 
would place the burden of ethical behavior on those pre-
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senting the information and not on those sponsoring its 
distribution.
To prevent improper revelation of the specific whereabouts 
of taxa linked to valuable TK, only minimal data should 
be cited. A disclaimer could be added to the label stat-
ing that to protect the best interests of the collaborating 
TK holders the investigators have withheld ethnomedical 
or geopositioning information. This allows for appropriate 
systematic evaluations to proceed without compromising 
either the value of the information or location of specific 
plant populations. To do otherwise could lead to the extir-
pation of valuable specimens and/or rare plants. 
Care must also be taken to protect the identity of speci-
mens undergoing screening for bioreactivity and chemical 
evaluations. Coding of these samples should not refer to 
the collection number but to another system of specimen 
identification devised especially for the purpose of keeping 
this linkage sequestered. This is a useful ploy especially if 
the specimens are being sent to several collaborating lab-
oratories and if the data that are generated are used for 
publications and presentations. Once appropriate studies 
have been completed, including both ethnobotanical and 
chemical dereplications and it becomes apparent that the 
knowledge is already well known, it may be appropriate 
to reveal the identity of certain specimens and their bio-
reactive compounds. These types of data are useful to 
researchers since they can serve to identify the common-
ality of certain valuable medicinal plants without compro-
mising the identity and worth of those that are exclusive 
to a particular group. Within this context such comparative 
treatises need not reveal unique nuances of preparation 
or combinations in formulations which might also confer 
value (Lewis et al. 2000). 
 As will be discussed below, in some countries, public pol-
icy and laws already mandate various forms of protection 
for holders of TK. For example, Peru recognizes that cer-
tain indigenous pharmacopeias were already published 
before their current law (8/10/2002 -#27811) protecting 
traditional knowledge was established. To accommodate 
this, Peru has evolved a graded scale of how remunera-
tion can be elicited. This is based upon the time of its re-
lease of up to 20 years preceding creation of the law and 
a standard rate thereafter. Considered as CK, a portion of 
this revenue generated from commercialization is to be 
allocated to a fund designated to promote the welfare of 
indigenous people. In this context it is unclear if the origi-
nators of this knowledge would be the recipients of any 
preferential benefits.
Data that are restricted to a particular group of individu-
als as “know how” are particularly valuable and must be 
carefully safeguarded. This is particularly challenging to 
investigators who require support to continue to evaluate 
the worth of this information so that the goal of reaching 
optimal benefits for TK holders can be reached. Treat-
ing TK as “know how” is a recent innovation (Lewis et al. 
2000) and few granting agencies and their reviewers fully 
understand the need to present this information in a form 
which will neither jeopardize its worth nor affect any fidu-
ciary restrictions which have been evolved between the 
investigators and TK holders. These obligations can limit 
the nature of information that can appear on grant applica-
tions in that the identity of plants or their compounds may 
only be able to appear in coded form. This necessity is in 
effect a “catch 22” in that certain reviewers, who are often 
under confidentiality constraints of the granting agencies 
themselves, do not always understand why this further re-
striction is necessary until patenting is achieved. There is 
a real risk that certain reviewers presented with this im-
plicit information may so dislike this approach that they 
do not take time to read the details of the proposal and 
the gross misinterpretations that result can adversely af-
fect funding possibilities. Also, the process of distribution 
and review does not necessary insure that information is 
appropriately safeguarded for tracing any inadvertent dis-
semination. This is particularly true for the U.S. National 
Institute of Health and other government review panels 
which can be large and made up of scientists from a cross 
section of academia and industry. Moreover, after fund-
ing, these grants are essentially in the public domain, and 
although there is some leeway in allowing only redacted 
copies to be distributed, there is always a concern that 
this approach lacks the necessary safeguards to prevent 
inadvertent dissemination of sensitive data. Private foun-
dations and industrial partners, sympathetic to these re-
straints, may be the few alternate resources available. 
In the evolution of protective mechanisms, there are quali-
fied uses of TK that must be considered either through 
customary use or agreements that are evolved between 
interested parties. There is a need to establish confiden-
tiality or non-disclosure agreements to protect potentially 
proprietary knowledge; to define how licensing arrange-
ments may evolve to either transfer to rights to an outside 
party as in an exclusive license, to allow the TK holders to 
maintain their rights through a sole licensing arrangement 
or with a non exclusive license. Outside contractors under-
taking bioprospecting should be aware that it is not always 
easy to identify all members of a group who may lay claim 
to specified TK or, for that matter, to evoke full consen-
sus from all concerned. There is always a risk that those 
initially ignored or unidentified during the contractual pro-
cess, or recalcitrant members of a group, may have sec-
ond thoughts once data and specimen collection are tak-
ing place and benefits are being realized (e.g., Kraho Indi-
ans of Brazil) (Hansen & VanFleet 2003). While the task of 
satisfying all concerned parties is likely to be challenging, 
and avoiding litigation not always possible, finding ways to 
rationally overcome these issues between the contracting 
parties and others in dissent is a logical solution so that 
appropriate evaluations can proceed. The goal should be 
to evolve a win-win situation rather than one where no 
one benefits. Customary law might be applied to answer-
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ing some of these questions and ultimately depends upon 
the legal status of the TK holders and how national laws 
govern these types of interactions. Generally, the notion of 
legal centralism stands in the way of complete recognition 
and enforcement of customary laws in states. However, 
the acknowledgement of indigenous land rights that has 
occurred in different fashion in a variety of countries (in-
cluding the Philippines, Australia and Brazil) may provide 
inspiration to identifying the legal tools to create a situa-
tion that is beneficial to all (Koopman 2005b). 
Changes in attitudes regarding these types of activities be-
gan to evolve in a substantial way in the early 1990s when 
professional societies (Table 2) and international legal in-
stitutions recognized that major changes would have to be 
made as holders of traditional knowledge became aware 
of their worth (Table 3). Noteworthy have been policies de-
rived from International Organizations such as the CBD, 
(Table 1), the UN (UN 1994), WHO, activities of WTO, the 
World Intellectual Property Organization (WIPO), and all 
their efforts to define and influence how these activities 
can be ethically, optimally and legally achieved through 
evolving laws and treaties. In South America, in particular, 
these guidelines to protect TK have also been followed 
by the evolution of certain regional laws encompassing a 
number of nations (e.g., Andean Community of Nations: 
Communidad Andina de Naciones or CAN), in addition to 
specific national laws (e.g., Peru, Venezuela, Brazil). In 
the pan-Pacific area, the Auckland Declaration will be the 
basis for similarly conceived laws (Anomymous 2004a).
Defining ownership of TK
Defining parameters of TK ownership is dependent upon 
the legal interpretation of current laws and policies. It is an 
evolving process with the goal of developing international 
mechanisms to ensure the protection of traditional knowl-
edge and folklore, as well as protecting genetic resourc-
es (WIPO 2005b). In the context of growing global needs 
against misappropriation and misuse, member states of 
the WIPO continue to address these issues through the 
Intergovernmental committee on Intellectual Property and 
Genetic Resources, Traditional Knowledge and Folklore 
(IGC) (WHO 2004a, WIP0 2005b). The United Nations 
draft declaration on indigenous rights, Article 29 states: 
“indigenous peoples are entitled to the recognition of the 
full ownership, control and protection of their cultural and 
intellectual property. They have the right to special mea-
sures to control, develop and protect their sciences, tech-
nologies and cultural manifestations, including human and 
other genetic resources, seeds, medicines, knowledge of 
the properties of fauna and flora, oral traditions, litera-
tures, designs and visual performing arts” (Anomymous 
1994, Hansen & VanFleet 2003, UN 1994). This declara-
tion and the related initiatives may perhaps be based on 
a variety of (international) public law instruments includ-
Table 2. Ethical Guidelines.
Year Convening Organizations Ethical Guidelines
1988 Society for Ethnobiology The Declaration of Belem.
1988 World Health Organization
International Union for the Conservation of Nature
World Wild Life Fund
Chiang Mai Declaration for Conservation of Medici-
nal Plants.
1990 Botany 2000 Herbarium Curation Workshop Code of Ethics for Foreign Collectors of Biological 
Samples.
1990 World Archaeological Congress Code of Ethics on Obligations to Indigenous Peo-
ples.
1991 Society for Economic Botany Professional Ethics on Obligations to Indigenous 
Peoples.
1992 National Institutes of Health & National Cancer Insti-
tute (USA)
Conclusion of a Workshop on Drug Development, Bi-
ological Diversity and Economic Growth.
1992 World Resources Institute
International Union for the Conservation of Nature
United Nations Environment Program
Global Biodiversity Strategy.
1992 American Society of Pharmacognosy Williamsburg Declaration.
1992 UNESCO Seminary on the Chemistry of the Rainfor-
est Plants
The Bukittingii Declaration.
1992 Seventh Asian Symposium on Medicinal Plants, 
Spices and Other Natural Products
Manila Declaration.
1993 World Wild Life Fund, UNESCO, Royal Botanic Gar-
den (Kew)
Guidelines for Equitable Partnerships in New Natu-
ral Products Development of the People and Plants 
Initiative.
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ing, of course, the CBC and those pertaining to human 
rights, which are arguably more important and far reach-
ing (Koopman 2005b). Currently, variations on this intent 
occur worldwide, however, there are limitations to the 
scope of legal directives, which may, for example, involve 
solely the protection of biological and genetic resources, 
to specific kinds of traditional knowledge, such as custom-
ary herbal medicine, images in handicrafts (Panama), to 
honoring cultural or spiritual sensitivities (e.g., New Zea-
land, Canada) (Havemann 1999). For example, title of TK 
may be claimed by the state, as it is in Madagascar and 
Viet Nam, in nations of Amazonia, India, and South Africa, 
considered the possession of indigenous groups or tribes, 
or in Tanzania, ascribed to specific healers. In Africa as a 
whole, appropriate management of TK related to genetic 
resources is still an evolving process. As was evident at 
the eighth session of the WIPO Intergovernmental Com-
mittee on Intellectual Property and Genetic Resources, 
agreement on many fundamental issues associated with 
protection, disclosure, evidence of prior informed consent, 
access, and benefit sharing has yet to be achieved (WIPO 
2005b). 
Variations are also apparent in the Western Hemisphere in 
that Brazilian law does not require documentation or reg-
istration of TK but mandates that TK holders must autho-
rize its transfer, licensing and assignment. Furthermore, 
the Brazilian Management Council requires that these ori-
gins be cited before access to genetic material is allowed. 
These mechanisms provide ways in which recipients of 
any potential benefits are identified. This law covers both 
TK known to indigenous groups as well as those derived 
following colonization (e.g., African-Brazilian origin). Cos-
ta Rican law regulates access and covers all intangible 
components whether it’s traditional or not, individual or 
collective, including knowledge related to genetic or bio-
chemical components. Alternately, Sui generis laws linked 
to biodiversity are narrowly defined in Peru (Law 28216), 
which restrict patents on its biological resources. There, 
concerns are primarily focused on patented botanicals 
that are sold elsewhere which utilize native Peruvian spe-
cies obtained illegally, or because they involve the unau-
thorized use, without compensation, of traditional knowl-
edge (Anonymous 2004b, WIP0 2005b). 
Challenges to Protecting 
Commercially Viable TK
While needs to evolve appropriate benefit-sharing mecha-
nisms are currently recognized, and definitive guidelines 
and laws are evolving, it will take the “test of time” to see 
how these are practically and fairly applied. Depending 
upon the country, ultimate protection of any concept with 
commercial potential can be conferred through trade se-
crets, petty patents, and patents. In many Amazonian 
countries, national laws, regional pacts, and international 
treaties now affirm the right to indigenous ownership of 
their traditional knowledge. There, examples exist of dis-
tinctive knowledge that is attributed to a particular popula-
tion associated with a tribe or clan, speaking a unique lan-
guage, which has historically resided in a circumscribed 
territory with limited interchange with other groups. Much 
of this information is not in the public domain. However, 
when indigenous groups claiming affiliation to one tribe 
reside in a number of neighboring countries, such as the 
San of Africa (Chennels 2003) or the Maya of Central 
America, challenges to establish ownership and appropri-
ate benefit sharing may be insurmountable unless all na-
tions involved within the traditional tribal territory are in 
agreement as to how this may be achieved. Less clear 
as to whom the beneficiaries may be are people linked 
together with a common language, but not necessarily 
by historical tribal affiliation, ethnic or national origin such 
Table 3. Intellectual Property Rights.
Year Intellectual Property Rights
1883-1967 World Intellectual Property Organization (WIPO)
1945 Agriculture Organization of the United Nations (FAO)
1961-1991 International Union of New Varieties of Plants Convention (UPOV)
1992 Convention of Biological Diversity and ad hoc group on Traditional Knowledge
1994 General Agreement on Tariffs and Trade (GATT)
1999 WIPO: Recognition of Traditional Knowledge and IP protection
2000 United Nations Conference on Trade and Development (UNCTAD)
2001 World Trade Organization (WTO), Trade Related Aspects of Intellectual Property Rights (TRIPS) Coun-
cil
1999, 2000 WIPO Fact Finding Mission to Peru, 1999 vs. a vs. ICBG-Peru agreements; published 2000
2002 Regional Pacts: e.g., Andean Community of WTO (Bolivia, Colombia, Ecuador, Peru and Venezuela) 
IP Law
2001, 2002 National Laws: e.g., South America - Brazil 2001; Peru 2002 
2004 Auckland Declaration
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as the Quichua speaking inhabitants of the Andes. Their 
pharmacopeia having evolved uniquely since colonization 
represents the collective traditional knowledge of many 
types of people. Therefore, should a new commercial en-
tity arise, some sort of regional benefit sharing might logi-
cally be the answer to the complex problem of identifying 
one or more suitable groups of beneficiaries.
Trade secrets and know how
It is appreciated that even indigenous TK is usually com-
munally and not exclusively held and there is always the 
risk of information being lost through advertent or inadver-
tent disclosure. However, the natural evolution of TK sug-
gests that this knowledge may only have value in a tem-
poral context. As time passes, there is always the risk of 
this information being independently discovered, “adulter-
ated”, or lost because of lack of need or skill levels to ap-
ply it. From a Western perspective, how many of us know, 
use, or apply useful knowledge considered as “old wives 
tales”, our grandmother’s, or great grandmother’s genera-
tion once valued? 
Nonetheless, evolving international law acknowledges 
that there is a need to protect TK from unauthorized ac-
cess, commercial use, third party claims, inappropriate 
cultural use, or misleading or deceptive practices. Many 
ways of protecting TK such as trade secrets or exclu-
sive “know how” to prevent nefarious exploitive activities 
must be evolved when using potentially proprietary TK. 
As a trade secret this knowledge can be kept secret in-
definitely, however, this method is vulnerable, to; indepen-
dent discovery, accidental or actual disclosure, or, in the 
case of certain phytochemicals, reverse-engineering. Ac-
cording to Koopman (2006), keeping TK secrets may be 
a way to prevent appropriation of the knowledge pursuant 
to US patent law but it will facilitate and ease appropria-
tion thereof by inventors that apply for European patents 
(i.e., given the absolute novelty standard applied under 
European patent law, all TK that been openly communi-
cated in whatever way, becomes part of the art, which is 
thus not the case with TK that is held secret). Also, keep-
ing knowledge entirely and/or rigidly secret may not be the 
most efficient manner of pursuing exploitation and, there-
fore, benefit sharing. Alternately, this information may be 
licensed for use. For example, a form of licensing agree-
ment was evolved between a Peruvian indigenous group 
and an American pharmaceutical company which utilized 
their specific proprietary “know how” during the evaluation 
of their medicinal plants for pharmaceutical potential. Dur-
ing a specified period these know-how licensing fees pro-
vided upfront remuneration to the communities involved 
and aided in many capacity building ventures (Lewis 
2000, Lewis & Ramani 2003, In Press).
Trademarks
Among current methods of protection, trademarks are 
being used widely to identify traditional originators. Un-
like forms of patenting it is an inexpensive way to protect 
the identity of the knowledge holder through an indication 
mark, not the knowledge itself. Appropriate contractual ar-
rangements can be made with those wishing to under-
take profitable ventures so that benefit sharing is ensured. 
Examples of this nature are medicinal balms which are 
sold in Viet Nam and the Russian Federation. In contrast, 
while certain North American First Nation or Indian tribes 
have evolved trademark protection regarding their art, this 
method has not been extended to uses of their medicinal 
plants, presumably because other types of healing ritu-
als are considered a necessary component of the process 
(e.g., use of energy medicine such as repetitive mantras) 
(Havemann 1999). 
Petty Patents
Petty patents (Table 4) are another, less-expensive mech-
anism which has been evolved in some countries to pro-
tect TK (Table 5). It is an ideal way to protect circum-
scribed botanical formulations for a limited period of time 
and provides the needed monopoly from 4-10 years when 
their marketing value is being established. In legal terms, 
a lower standard of inventiveness can be applied, how-
ever, the claims must define the invention as having an 
“innovative step” which is a substantial contribution to the 
art, yet it need not be non-obvious. These claims are reg-
istered and examination is only required prior to enforce-
ment. Currently there are no international agreements to 
facilitate these types of applications and only a few thou-
sand are registered each year. 
Patents
Table 4. Petty Patents.
Legal mechanism to protect TK
Ideal for circumscribed botanical formulations
Lower standard of inventiveness applied
Claims must define an invention as having an “innovative step,” which is a substantial contribution to the art, 
need not be non-obvious, and is less stringent than an “inventive step”
Registration system, examination only required prior to enforcement
Less expensive to apply
Known to select countries worldwide
No international agreements to facilitate applications; only a few thousand registered each year 
•
•
•
•
•
•
•
•
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Distinctions between a patentable invention and an un-
patentable discovery are frequently debated (Koopman 
2005a) and there is a growing consensus that reformula-
tion of current patent laws are needed to accommodate 
these challenges, particularly as it related to the utiliza-
tion of biotechnological inventions that involve TK (Sher-
man & Bentley 1999). While nuances of patent law may 
differ from one country to another, in general terms it is a 
legal certificate that authorizes its holder to exclude others 
from commercially using the underlying inventions. The 
certificate can be granted for products as such, the uses 
thereof, and processes. Different requirements, such as 
pertaining to the novelty and non-obviousness of the in-
vention, must be met before the certificate could be grant-
ed. This is an expensive process not only to initiate but 
also to provide oversight from untoward encroachment 
over the 17-20 years of its lifetime. In order to extend the 
longevity of a certain invention, additional (minor) inven-
tive steps may be taken as to enable acquisition of a new 
patent for a not so different invention. Some consider this 
practice to be an example of how the patent system can 
be abused so as to serve the private interests of the pat-
entees (Koopman 2006). International patents afford the 
most comprehensive protection (de Carvalho 2003). 
To many, the application of a utility patent to any type of 
TK is an oxymoron, because “inventorship” cannot be as-
cribed to persons conveying this type of knowledge, or the 
plant/s that are used. Moreover, there are issues of con-
veying different types of proprietary rights – thus excluvity 
– to different resources of research and development and 
the subsequent conflict of rights that may occur. Changes 
in the law have been proposed through the TRIPS agree-
ment to accommodate the rights of TK holders sharing 
community knowledge by specifying its source (Lewis & 
Ramani 2003, In Press, Quinn 2001). While some groups 
may consider this method as being culturally inappropri-
ate, others may welcome this protection as a way to im-
prove their livelihood (Koopman 2005a). Also, issues of 
dissension frequently occur over a misunderstanding of 
the process, with concerns erroneously arising over be-
liefs that restrictions to traditional uses have occurred. An 
early example, frequently cited as biopiracy, is the 1992 
W. R. Grace patent (US 5124349) associated with the 
process of stabilizing compounds, such as azadirachtin, 
in Azadarachta indica (neem) seeds and its oil for use 
as insecticides. According to Robert Larson, President of 
Vikwood Ltd whose company in 1985 originally invented 
a similar stabilizing method from neem seed extracts (US 
4556562), the controversy was incited by the Indian me-
dia and outraged Indian farmers who were encouraged to 
erroneously believe that patenting would impair their tradi-
tional uses of crude neem products for the same purpos-
es. Nothing could have been further from the truth. It took 
time for this misunderstanding to be resolved. What be-
came clear was that while the bioreactivity of these com-
pounds had already been identified and widely acknowl-
edged, they were unstable in extracted form and thus not 
commercially viable. The invention claimed in the W.R. 
Grace patent was related to the process of their stabili-
zation and was unknown to scientists in India and else-
where. Therefore assertions being perpetrated that the in-
vention was “not new” could not be substantiated within 
the context of the US relative novelty rule or patent law 
which allows inventions based on knowledge present in 
the public domain to be patented. As a result of this inven-
tion, similar neem-related patents, generated primarily by 
Indian scientists, were evolved in the US and elsewhere. 
With the birth of a new industry and the increased need 
for raw material, both the owners of the patents and lo-
cal farmers in India and other countries where plantations 
of the neem tree grow, have benefited considerably (Mc-
Manis In Press). Also, confusion to rights to “ownership” 
of knowledge related to the use of a medicinal plant may 
arise when others, to affirm the criteria of the discovery 
being “non-obvious” to a person “skilled in the art,” add 
necessary inventive steps leading to novel discoveries 
such as identifying and using only the natural bioreactive 
compound or further developing semi-synthetic or syn-
thetic molecules which have greater marketing potential. 
Table 5. Countries were Petty Patents Exist.
AFRICA Ethiopia, Kenya, Organisation Africaine de la Propriété Intellectuelle (Republics of Camer-
oon, Central Africa, Chad, Congo, Dahomey, d’Ivoire, Gabon, Malagasy, Mauritania, Niger, 
Senegal, Upper Volta). 
CARIBBEAN Trinidad & Tobago
CENTRAL AMERICA Costa Rica, Guatemala, Mexico
CENTRAL ASIA Kazakhstan, Kyrgyzstan, Tajikistan, Uzbekistan
EAST ASIA China, Japan, Korea, Malaysia, Philippines, Thailand
EUROPE Austria, Belarus, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, 
Georgia, Germany, Greece, Hungary, Ireland, Italy, Montenegro, Netherlands, Poland, Portu-
gal, Republic of Moldova, Russian Federation, Serbia, Slovakia, Spain, Turkey, Ukraine
OCEANIA Australia (now redefined as “Innovation” Patents)
SOUTH AMERICA Argentina, Brazil, Colombia, Peru, Uruguay
SOUTHWEST ASIA Armenia
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This, of course, was not the case with azadirachtin from 
neem, since its value as an insecticide was already well 
known in India before the European patent on its use was 
granted and eventually rescinded. 
In certain instances linkage to relevant TK may not be cit-
ed in the patent, or overlooked by patent examiners who 
must rely on currently available, but generally ambiguous, 
databases (Band 1997, Koopman 2005a). Advertent over-
sights or otherwise, it is not always easy to define the iden-
tity of just one nation of origin or all relevant stakeholders, 
who might be worthy of sharing in the benefits accrued 
from a patented discovery. This is particularly true when 
inventions are made from taxa that are cosmopolitan or 
widespread in distribution (Vogel 1996), when the biore-
active compounds in question can be found in disparate 
taxa, or where TK linked to the patent is generally known. 
To be fair, review of released patents to assure that biopi-
racy has not occurred should be carefully and rationally 
vetted before accusations of misconduct are made.
To overcome some of these issues when circumscribed 
TK is used, its “owners” who transmitted this knowledge 
(under the mandates of prior informed consent) can be 
cited in the preamble of the patent and apportionment of 
ownership assigned to an appropriate juridical body rep-
resenting the indigenous group or groups. This model 
builds on the existing statutory possibilities of conveyance 
of patents to multiple inventors (shared inventorship/pat-
ents). However, this does not affect the claim to the un-
derlying invention by the patentee – the preamble only 
has interpretative relevancy. Examples of how this can 
be achieved will be found in a current patent application 
now under examination in the U.S. Patent and Trademark 
Office which involves discoveries made during the Peru-
ICBG project regarding bioreactive compounds found in 
Aguaruna malaria remedies. This patent recognized the 
contribution of their know-how to the inventions, names 
those providing the information, and assigns the owner-
ship to the confederation of indigenous peoples to which 
they belong as well as to the three collaborating universi-
ties that worked towards these discoveries. Benefits ac-
cruing from any commercial development would there-
fore be equally shared between all four entities, with three 
quarters of the revenue being returned to the host coun-
try through its two academic institutions and indigenous 
participants (Lewis & Ramani 2003, In Press, McManis 
2003). Within the context of understanding between these 
partners and any future patents that are likely to be gen-
erated, issues related to identifying types of commercial-
ization, how and when enforcement will be applied, and 
who will bear the costs incurred, continue to be matters of 
mutual discourse.
Evolving these types of utility-based patents rewards 
those who have amplified this original value linking TK to 
the discovery of, for example, a useful phytochemical. It 
provides a mechanism by which “know how” not only has 
value but in which ownership can be shared between TK 
holders and those that provided the value-added technol-
ogy required to reduce these concepts into a potentially 
viable commercial entities. Therefore ownership and in-
ventorship should not be confused and how benefits are 
apportioned as related to TK linked patents depends upon 
how the totality of “inventorship” and “ownership” is as-
signed to all those involved in the inventive process. In 
the process of “reducing to practice,” added value is likely 
to evolve in many ways not only by the discovery of the 
active component/s in the original plant or other taxa, but 
also if any added uses and formulations are evolved, etc. 
Within this context there is considerable difference be-
tween the investment required to develop a commercial 
product utilizing raw material, natural products designed 
to amplify the worth of known phytochemicals (e.g., phyto-
pharmaceuticals), or the development of pharmaceuticals 
that must overcome hurdles of research, development 
and regulatory processes, so as to ensure parameters of 
use, safety, and efficacy. As long as the expectations of all 
stakeholders are not realistically addressed and satisfied, 
creating the appropriate compensatory formulae will be 
subject to challenge. 
 
In contrast to the majority of other countries that establish 
priority of inventorship based on the “first to file,” the US 
concedes priority to those providing temporal proof of be-
ing the “first to invent.” In order to provide parity with for-
eign applicants under the GATT Uruguay Round Agree-
ments and to provide more time to file, the US provisional 
patent was evolved in 1995 to harmonize these two points 
of view. This is an invaluable mechanism for university in-
vestigators and their students who can utilize this as a 
means to establish an early filing date and allow the term 
“patent pending” to be applied in a doctoral dissertation 
or allied presentation. For academic purposes, this pro-
visional patent is otherwise, non-public, and “filing is per-
mitted without a formal patent claim, oath or declaration, 
or any information disclosure (prior art) statement “ (www.
uspppto.gov/web/offices/pac/provapp.html). This low-cost 
method protects proprietorial traditional knowledge during 
a critical but short period of time when certain information 
is being considered as being worthy of undergoing the 
more prolonged and expensive process of a non-provi-
sional patent application. While many of these provisional 
patents never realize a non-provisional submission, this 
non-extendable, 12-month pendency period provides, 
within this time frame, the opportunity to either convert to 
a non-provisional patent status or file for this separately. 
There are advantages to both in that the first way applies 
the original filing date to the inventive process whereas 
the latter prolongs the time for up to 12 months in which 
the non-provisional patent can be extended. Whatever the 
case, claims in the provisional patent must support the 
subject matter on the non-provisional patent application. 
Also, both provisional patents and full patent applications 
can be categorized as non-public, thereby safe-guarding 
the dissemination of this information further (Anonymous 
1995, Bitlaw 2005, Brown & Michaels 2005, Ladas & Per-
ry 2005).
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Sui Generis Laws
Sui generis laws, defining access to indigenous and na-
tional TK are evolving so that respect and preservation 
of this information is assured during the period where as-
pects for its wider application and means to provide fair 
and equitable benefit sharing are being explored. Includ-
ed in these laws can be regulations which acknowledge 
the need to recognize and protect the rights of peoples 
who have evolved this TK and any genetic resources that 
may be associated with its use. There is a growing recog-
nition that these tangible resources must be conserved, 
used in a sustainable manner, protected, and subject to 
forms of legal transfer. Furthermore, in order to encour-
age sustainable development and capacity building and 
to promote additional expansion and innovativeness with-
in communities of TK holders, appropriate mechanisms 
of benefit sharing need to be mandated. These would in-
clude defining the type of start-up/upfront benefits, mile-
stone payments, and product benefits through royalty 
payments. Remuneration may be in some form of finan-
cial arrangement placed in a trust fund to support com-
munity development projects and training, or by providing 
equipment (e.g., computers/software, solar panels). Ca-
pacity building can take many forms from providing better 
educational and health opportunities for all to encouraging 
the development of new crops (e.g., medicinal plants) and 
cottage-based industries related to these activities. Within 
this context, opportunities to train local parataxonomists 
and paraethnobotanists to aid in these endeavors may 
evolve. For example, improving the quality of TK-based 
products could result in removing low-quality traditional 
medicines from the marketplace as well as providing a 
mechanism whereby income is generated from the sale 
of superior products. While these innovative laws are ethi-
cally derived, many require further refinement so that they 
can be practically executed (Lewis et al. 2000). 
The Requirement (as a Proposed 
Modification of Patent Law)
There is a proposed change in patent law being consid-
ered by WTO member states. Currently, disclosure is re-
quired only if necessary to explain the invention or the 
“best mode” of protecting it. Full disclosure of TK-associ-
ated genetic resources, in what is referred to as the “Re-
quirement,” is considered as an accessory which relates 
to the invention cited in the patent collaterally. This in-
volves citing the origin of the genetic resources and pro-
viding proof that “prior informed consent” has been elicit-
ed from the TK holders of this utility-linked knowledge. Ac-
cording to de Carvahlo (2003) “it is not ancillary to patent 
law…it is ancillary to administrative and/or contract law.” 
He further believes that non-disclosure of this informa-
tion would constitute fraud and cause the application be 
considered an “abuse of rights.” To be consistent with the 
TRIPS Agreement, he further proposes that disclosure of 
origin and prior informed consent be made a condition of 
enforcing the patent rather than imposing these require-
ments as a condition of patentability (de Carvalho 2000). 
Whether or not this proposal has any material effect, or 
may violate TRIPS, remains to be ascertained (Koopman 
2006). As mentioned previously, several European coun-
tries are addressing issues related to the Requirement, 
with the intent of changing their patent laws accordingly. 
There is a variation of how this need is perceived, since 
some countries may not make this a formal condition or 
restrict it only to patents, or other areas of industrial prop-
erty law, such as plant breeders rights (Table 6). 
These criteria are important when natural genetic resourc-
es conserved in situ are employed but not necessarily 
when ex situ conserved resources are utilized. Moreover, 
the linkage between the invention and the resources may 
become weakened sufficiently to be insignificant when 
active components are isolated or synthesized. However, 
Table 6. The Requirement.
In the evolution of patents involving TK-linked knowledge to genetic resources, certain WTO member states “require”, 
disclosure of the origin of this material as well as evidence that previous informed consent of TK holders has been 
elicited. It is considered an accessory, which relates to the invention collaterally. To do otherwise would constitute 
fraud and cause the application to be considered an “abuse of rights” (de Carvalho 2000).
Member States that make the Requirement a formal condition of patentability: Andean Community (Bolivia,
Colombia, Ecuador, Peru and Venezuela), Costa Rica, Egypt, and India.
Countries that impose the Requirement but not as a formal condition of patentability: People’s Republic of 
China, 15 members of the European community.
Countries that apply the Requirement in the field of patents only: Peru, Egypt, India and the European Com-
munity. 
Countries that extend the Requirement to other areas of industrial property law: Community of Andean Na-
tions, Brazil, Costa Rica e.g., plant breeder’s rights, and where it applies, utility model protection.
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patents in the chemical field may be affected should the 
Requirement, such as Andean Decision No. 391, which 
covers genetic resources, derived products, and sub-
stances as well, be pertinent to the patent application (de 
Carvalho 2000, SICE 2005). 
Implementation of the Requirement
The evolution of Andean Decision No. 391 has done 
much to promote cooperation among neighboring signa-
ture countries, namely Peru, Bolivia, Ecuador, Colombia 
and Venezuela, and has laid the foundation for the de-
velopment of regional strategies needed to protect their 
common genetic resources and traditional knowledge. A 
number of major challenges remain since not all signature 
countries (e.g., Peru and Ecuador) have yet been able to 
implement Andean Decision No. 391. So that regulations 
are consistent and practically applied, progress needs to 
be made within the Andean Community by promoting the 
development of appropriate supplementary legislation for 
the protection of traditional knowledge, standardizing the 
handling of data and information so that variations in qual-
ity are diminished and ways to access are evolved, devel-
oping mechanisms to overcome institutional limitations, 
as well as accommodating interpretative variations to the 
Decision’s intent (Anonymous 1997, Berendson 2000, 
Molina 2005, SICE 2005).
The Andean Decision evolved out of the Commission of 
the Cartagena Agreement signed in 1969 (SICE 2005) 
and involves a trading bloc of South American countries, 
namely Peru, Ecuador, Bolivia, Colombia, and Venezuela. 
Formerly referred to as the Andean Pact, it is called the 
Andean Community of Nations (CAN). This bloc and an-
other referred to as Mercosur, encompass the countries of 
Brazil, Argentina, Uruguay and Paraguay, and in addition 
to Chile will become the South American Community of 
Nations. This is expected to evolve within the next decade 
into the South American Free Trade Area (SAFTA). Pat-
terned after the European Union, it is likely that harmo-
nization of policies regarding TK-linked genetic resourc-
es will take place within this group and eventually with 
adjacent nations and trading blocs in Central and North 
America.
As a part of this process, registration of TK knowledge has 
been proposed. While private registration has its merits in 
providing protection and enforceability, there are risks to 
certain time-frame impositions. The burden to communi-
ties to legally protect this information may be impractical 
and the potential always exists that loss of benefits can 
result from advertent or inadvertent dissemination. When 
formalities are not imposed, automatic protection may be 
more difficult to enforce. In countries such as Panama, 
Peru, Thailand, and the USA, specific criteria regarding 
protection are outlined whereas other nations may not 
specify which conditions apply (Africa Model Legislation, 
Costa Rica, Phillippines) (Alexander et al. 2003, Chan-
robles 2004, WIP0 2005b). For example, Costa Rica’s sui 
generis system law of 1998 does not require prior decla-
ration, explicit recognition, or official registration in order 
to protect the knowledge, practices and innovations of in-
digenous peoples and communities related to their use 
of components of biodiversity and associated knowledge 
(Hansen & VanFleet 2003). 
 In Ecuador, a Knowledge Cartel is being devised so that 
TK is kept in individualized community data banks which 
are safeguarded from access by others. The intent is 
to review all the collected knowledge for the purpose of 
identifying information that is either common to multiple 
communities or unique. Any distinctive knowledge will be 
considered a trade secret and any use generated through 
material transfer agreements or licensing could be used 
as the source of benefits to be shared by the contributors 
and the Government of Ecuador (Vogel 1996). This con-
cept has its limitations in not recognizing that commonal-
ity is more likely to exist within related clan communities 
or tribal affiliations and that uniqueness within this context 
should accommodate a broader benefit base (Elvin-Lewis 
2003). It would be a rare event indeed for only one com-
munity to have knowledge that is not known to its rela-
tives elsewhere. Usually the utilization of a trade secret is 
combined with some form of licensing or royalty payment 
that might extend even if the knowledge enters the public 
domain (e.g., Listerine) (Hansen & VanFleet 2003). Also, 
when such a codicil does not exist, remuneration may still 
be accrued should a breach of confidence, resulting in its 
release into the public domain, be linked to malicious in-
tent of the contracting party (WIPO 2002a). 
Alternately, when public registration is employed “for the 
common good,” it becomes prior art and thus negates the 
application of intellectual property rights on TK prior to 
patent approval. However, placing this knowledge in the 
public domain can result in the loss of its potential com-
mercial value to community members since it can be used 
by anyone without permission. For example, in India, an 
ongoing public registry is taking place called the People’s 
Biodiversity Registers (PBRs) as recognized in the Indian 
Biological Diversity Bill of 2000. With the intent of register-
ing this information as prior art, the nation’s knowledge of 
“biodiversity, its usage, trade, and efforts for its conserva-
tion and sustainable utilization” is being recorded in com-
puterized data bases. This activity is taking place from the 
village level upward and is designed to provide informa-
tion to the public, government, and industry (Hansen & 
VanFleet 2003).
The format of this registration and the information pro-
vided is not universal. Current databases, including those 
electronically devised, vary widely in composition and it 
would be ideal if they were similarly constructed, suitably 
organized, interactive, and sufficiently large enough to 
satisfy the need to make “prior art” searches achievable. 
According to de Carvalho (2003) they “may be the prod-
uct of creative activity” as related to the original selection 
and arrangement of data and thus would be protected by 
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copyright according to the Berne convention, Article 2.5, 
the TRIPS agreement Article 10.2, and the WIPO copy-
right treaty (WCT) of 1996 (Article 5). With the exception 
of the European Union, non-original contents of the data-
bases are not protectible. It would be invaluable if specific 
plant data were comprehensive enough to describe its tra-
ditional uses, knowledge or practices, and also provide in-
formation on how related taxa within the context of region-
al biodiversity are used similarly. The design is critical, as 
is the correctness of the data, in order to satisfy a pat-
ent examiner who needs the information in a technically 
useful manner to determine “novelty.” Simply dumping un-
edited and diffuse information into the patent examiners 
hands would have little, if any, value. Also, with the ever-
evolving state of data management, consideration should 
be made to accommodate changes in this technology so 
that whatever is being stored has long-term accessibility. 
At this time, WIPO does not warrant “the accuracy reliabil-
ity, correctness, currency, completeness, or correct trans-
lation into English of its current TK databases” evolved 
from Chinese and Indian sources (www.wipo.org/ipdl/en). 
Eventually a standard format to complement appropriate 
electronic data processing might be evolved to make this 
task easier(WIPO 2002a).
 
Private database management is particularly problemati-
cal since issues to safeguard these data in a defensible 
manner will always be challenging. A certain level of pro-
tection of TK may be afforded through Article 39.3 of the 
WTO’s TRIPS agreement. Article 39 involves issues re-
lated to “know how” or trade secrets, and 39.3 concerns 
governmental obligations to protect undisclosed informa-
tion from unfair commercial use. However, if these record-
ed data are not kept within the confines of the indigenous 
people, protection would be given to the proprietor of the 
database rather than to them. Losing control of their tan-
gible assets is a major concern since access to this in-
formation will always be vulnerable to temporal policies 
associated with the shifting roles of gatekeepers and key 
holders and their interpretation of their responsibilities. 
For purposes of patent examination, it has been suggest-
ed by WIPO delegates from Bolivia, Brazil, Panama, and 
Venezuela, that this aspect be conducted under an obliga-
tion of confidentiality (WIPO 2002a). However, when su-
pervision is ceded to governments, there is not any guar-
antee that their commitment to appropriately administer 
this information will be honored. This is particularly true 
if certain administrations prove to be unstable and are 
subject to self-serving policies and corruption. Within the 
broad scope of TK, the highly codified and widely docu-
mented state of traditional medicine practices may make 
developing appropriate registries on this aspect easier to 
achieve (Alexander et al. 2003, de Carvalho 2003). While 
the intent may exist, the complexities of harmonizing na-
tional CK with that of circumscribed or overlapping TK so 
that benefits are fairly and equitably distributed may be 
unmanageable. According to Portuguese Decree-Law 
No. 118/2002, this separation is resolved by identifying 
the date on which TK is first publicly exploited as having 
precedence over the date in which public disclosure was 
Table 7. Traditional Knowledge protection through Defensive databases.
Collection and organization of elements of TK in databases in a manner so as to permit their retrieval by trademark 
and patent examiners in consideration as prior art or as bars to registration.
INDIA: Database of traditional Aryuvedic medicine at WIPO website. People’s Biodiversity Registers.
PEOPLES REPUBLIC of CHINA: Database of traditional medicine at WIPO website.
PERU: TK in public domain (collective knowledge) to be submitted to all patent offices worldwide and is voluntary. No 
safeguards regarding how “secrecy” could be assured for proprietary indigenous databases.
PORTUGAL: Permits TK databases to be kept secret, with information protected by unfair competition law, and will 
not give rise to exclusive rights. What separates TK that is new from TK in the public domain is not the date of disclo-
sure, but the date on which it was first commercially exploited.
SOUTH ASIA: Health Heritage Test Database contains non-patent and patent literature, as prior art, on 50 medicinal 
plants and their traditional uses. 
VENEZUELA: Held secret until appropriate system of TK protection evolves internationally. Biozulua means “house 
of secrecy” or “house of wisdom” and is protects TK databases of medicinal and agriculture nature. Mechanisms to 
access have yet to be evolved.
EVOLVING DATABASES: Africa,Australia
Table 8. Peruvian Traditional Knowledge Laws.
#26839 - 7/97. Establishes the State’s sovereignty with regard to conservation of biodiversity and its sustainable use, 
but those rights to biological resources does not give the right to genetic resources without state approval.
Establishes that TK is cultural patrimony requiring protection.
#27811 -8/10/2002. Establishes a special protections regime for the collective knowledge of indigenous peoples that 
is connected with biological resources. Does not affect traditional exchange between indigenous peoples.
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made (de Carvalho 2003). This is an evolving process that 
is deserving of patience. 
 
Defensive Data Bases
A number of countries are developing defensive databas-
es to assure that appropriate benefit sharing strategies 
are evolved for holders of collective knowledge (Table 7). 
Many, such as the BioZulua (House of Wisdom) in Ven-
ezuela, are still being kept secret until an appropriate sys-
tem of TK protection is evolved internationally. Others, like 
the new legislation evolved in Peru, namely #27811 and 
#26839 (Table 8), are much more complex. While many 
of the aspects of #27811 are to be applauded (Table 9), 
other features are likely to be problematical and warrant 
refining (Table 10). 
For example, unlike Brazil, for its Afro-Brazilian popula-
tions, Peru has yet to address issues of other circum-
scribed inventive populations within their borders and 
only defines it in terms of indigenous origins, which refer 
to populations existing prior to the formation of the Pe-
ruvian State, who acknowledge specific tribal affiliations 
by maintaining distinct cultures, and occupying specific 
territorial areas. These include people in voluntary iso-
lation or those living in rural and native communities. 
Ethnobotanical data suggests otherwise. The research of 
Dr. Walter Lewis and myself provides numerous examples 
from Peru that indicate that access to the same flora, and 
plant introductions and concepts from elsewhere, have 
significantly influenced both the indigenous and other 
unique national pharmacopeias for more than 500 years 
(Elvin-Lewis et al. 2002, Lewis 2000). Restricting benefits 
related to the commercialization of CK to only Peruvian 
indigenous group merits reconsideration since their will al-
ways be challenges to original “inventorship” or added in-
novations which might not apply to the creative ingenuity 
of indigenous groups. Therefore, there is a need to affect 
a logical compromise to accommodate other sources of 
CK so that distributions of revenues are more equitably 
achieved. Within this context it is logical that the Indige-
nous Fund continues to be utilized for its original purpose, 
but only when proof of indigenous origins for any commer-
cialized CK is clearly evident. 
According to current Peruvian law, the bases of revenue 
for this Indigenous Fund are to be derived from three 
types of sources. A graded formulation has been devised 
Table 9. Objectives of Peru-Law #27811. Recognizes rights and power of indigenous peoples to dispose of their TK as 
they wish.
To promote respect for and the protection, preservation, wider application and development of indigenous TK.
To promote the fair and equitable distribution of the benefits derived from the use of that TK.
To promote the use of the knowledge for the benefit of the indigenous peoples and mankind in general.
To ensure that use of TK is elicited with prior informed consent. 
To promote the appropriate distribution of benefits within the indigenous context through the creation of an In-
digenous Fund.
To prevent patents being granted without acknowledgement of TK as being a part of prior art in the examination 
of the novelty and inventiveness through evolution of forms of “protective data bases”.
•
•
•
•
•
•
Table 10. Peruvian Law #2781: Problematical Areas.
Evolution of Defensive Databases: examination of claimed TK as to its novelty: disclosed TK will integrate a public 
inventory; undisclosed TK will be kept in sequestered databases. 
Royalty or Licensing Fees handled by the Peruvian government agency,  INDECOPI (Instituto Nacional de De-
fensa de la Competencia y de la Protecion de la Propiedad Intelectual) are exclusive of collecting fees etc., related to 
use of natural resources governed by another agency, INRENA  (Instituto Nacional de Recursos Naturales).
INDECOPI in Offices of Inventions and New Technology will oversee databases and serve as registry of all 
contracts and agreements.
“A percentage which shall not be less than 10% of the value before tax, of the gross sales resulting from the mar-
keting of goods developed on the basis of collective knowledge.” 
The parties may agree on a greater percentage according to the degree of direct use or incorporation of the said 
knowledge in the resulting end product and the degree to which the said knowledge contributed to the reduction 
of the cost of R&D on derived products among other things.”  
The licensing agreement shall provide compensation of indigenous people for the use of their collective knowl-
edge (“know-how”); such compensation shall include an initial or monetary or other equivalent payment for 
sustainable development and a percentage of not less than 5% of gross sales before tax for the marketing of 
goods.
CK in public domain for more than 20 years: 10%
CK in public domain for less than 20 years: 10% +
TK not in public domain associated with distinct indigenous group: 10% + 5%
Revenue to be placed (exclusively) into Fund for Development of Indigenous Peoples.
•
•
•
•
•
•
•
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in which proprietary TK is valued the highest, but also rec-
ognizes that CK that has been known for up to 20 years 
as having greater value, than others acknowledged as be-
ing older. How this might be applied in practice is likely 
to be challenging. The formulae for acquiring revenue for 
this fund are based on gross sales, rather than through 
apportionment of licensing, royalty fees, or net sales of 
a botanical. While it is conceivable that certain novel bo-
tanicals may fit into this category, if sales are locally moni-
tored, oversight of exports that generate revenue may not 
be readily achieved. Unfortunately, many view this policy 
as being unrealistic, particularly if the development of a 
pharmaceutical is involved where lesser percentages are 
more realistic, and consider it as effectively discouraging 
commercial investment. In the case of any new pharma-
ceutical, for example, milestone payments during the evo-
lutionary process, apportionment of royalty revenues, and 
lower drug costs to the contributing indigenous group or 
groups may be more pragmatic ways of developing fair 
compensatory arrangements. Whatever the final outcome, 
appropriate management of derived revenues is essential 
and policies which promote control by government agen-
cies, while well intentioned, may not satisfy certain indig-
enous organizations who may wish to take control of this 
aspect themselves. 
 
Also, the intent of Peruvians to register national CK in pat-
ent offices worldwide, as is being accomplished for the 
long-established pharmacopeias of India and China, may 
not be a logical solution to provide protection for its reg-
istration as “prior art.” Unlike these well-documented tra-
ditional systems, Peruvian CK has yet to be similarly as-
sembled. In order to achieve this goal, a commitment of 
time, effort and money by Peruvian authorities would be 
required to first collate this information into a suitable and 
accessible database. Providing data in an unedited form 
would impose an enormous burden on patent offices that 
would be unlikely to have the resources to utilize these 
data as envisioned. Also, like medicinal-plant CK in many 
South American countries, Peruvian CK is not widely 
known, but nonetheless may be shared with neighboring 
countries who are not necessarily members of the Andean 
community of nations or CAN (e.g., Brazil). Making claim 
to its exclusivity may invite challenges by other nations 
who share the same flora, ethnic groups and concepts, 
and who may prefer to manage this information differently 
(e.g., Ecuador). An accord is needed within member na-
tions of CAN and other adjacent countries on how this 
aspect should be managed before registration proceeds. 
In the interim, since the WIPO requires that patent appli-
cations cite the origin of any plant, examiners might re-
quest Peru or other adjacent countries to indemnify that 
a review of their available TK or CK databases has taken 
place and that linkage to “prior art” does not exist. 
As it stands, Peruvian law does not prevent indigenous 
groups from evolving proprietorial defensive databases 
which they control. Evoked under prior informed consent, 
it is possible for information regarding the traditional use 
of medicinal plants and/or healing ceremonies to be “li-
censed” as utility linked “know-how” and other data kept 
secret. The know-how licensing agreement evolved dur-
ing the ICBG-Peru project is a primary example of how 
this was achieved between the participating indigenous 
group and commercial entities. During the medicinal eval-
uation period of their plant extracts, linked to their TK, par-
ticipating communities used these milestone payments for 
educational purposes and capacity building projects, in-
cluding the training of paraethnobotanists and parataxon-
omists that could continue the work in the future. Access 
to this knowledge also provided collaborating scientists 
with ways to strengthen their investigations by applying 
suitable disease-targeted assays and phylogenetic ampli-
fication techniques. Moreover, acknowledgement of their 
TK was cited in the preamble of a current pending US pat-
ent/s. These concepts served as the template for much of 
the Peruvian law 27811 as described above. 
Institutional Databases
A number of academic-housed databases have been 
compiling information on the chemistry, pharmacology, 
biological activity, taxonomic, geographical distribution, 
ethnobotanical and ethnomedical uses of a wide variety 
of natural products and microorganisms. This information, 
which continues to be regularly compiled from published 
research papers, is an invaluable resource to the scientific 
community. These assets enable investigators to conduct 
suitable dereplications in order to determine the scope of 
research which has been conducted on particular natural 
products and their components. The TK that accompanies 
this information has already been put into the public do-
main by virtue of publication, and as secondary data its 
distribution in this manner should not be in contest. The 
Natural Products Alert (NAPRALERT) at the University 
of Illinois, Chicago, the CABI Medicinal Plant Database 
in Wallingford, UK, and MEDLINE are notable examples 
of those freely accessible sources. In contrast, BioZulua 
in Venezuela, established by the Fundaciōn para el De-
sarrollo de las Cienceia Fisicas y Naturales (FUDECI), is 
proprietary with restricted rights to use (Alexander et al. 
2003). 
Need for International Repository for TK or CK
Yet to be addressed by international agencies are ways 
in which TK or CK (other than Asian Medicinal Systems) 
might be catalogued independently from national regis-
tries. While utilization of WHO and WIPO databases may 
be appropriate for CK, making sure these data are accu-
rate, interactive and accessible is a massive undertaking. 
There is a critical need for the creation of a suitable inter-
national repository for safeguarding proprietary TK that is 
now at risk of being lost because certain groups lack the 
resources for management of these data themselves. In 
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most countries national registries do not exist, and when 
they do, certain indigenous groups may prefer not to uti-
lize them due to their sense of independence, or lack 
of confidence in what has evolved. This issue becomes 
more complex when certain ethnic groups live beyond the 
borders of one nation. By allowing their data to be stored 
in this manner, they are also establishing its existence and 
their “nation state ownership” within a temporal context. 
Anyone wishing to establish a dialogue with current stake-
holders for purposes of accessing this knowledge for po-
tential profitable enterprises would have a way of doing 
so. For example, based on a pre-arranged fee or other 
monetary and legal arrangements, restrictive access to 
their know-how might be permitted so that current stake-
holders could benefit directly. Moreover, to reimburse the 
repository, a user fee might be assessed each time a par-
ticular database is used in this fashion. Ultimately, when 
appropriate policies are evolved, registration within the 
auspices of the WIPO might be a way of establishing the 
knowledge as “prior art.” A list of currently available data-
bases is provided in Table 11.
Conclusion
Evolving mechanisms and laws are beginning to impact 
on how TK and CK can be utilized to achieve appropriate 
benefits for those who are custodians of these types of 
information. This is not an easy task since issues related 
to ownership and ways to ensure appropriate protection, 
oversight and disbursement of the revenues are always 
likely to arise. “The premise of biodiversity prospecting is 
that appropriate policies and institutions are needed to en-
sure that the commercial value obtained from genetic and 
biochemical resources are a positive force for develop-
ment and conservation” (Reid et al. 1993). Much depends 
upon the application of current national and internation-
al laws and the acceptance within and among nations to 
work towards logical solutions. Critical to this evolving 
process is the acknowledgement that a great deal of valu-
able TK is being lost not only by its unsuitable dissemina-
tion but because a fitting international repository does not 
exist to safeguard this knowledge while workable options 
to address its worth are being examined. 
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